Compare Indoco Remedies with Geojit BNP Paribas - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs GEOJIT FINANCIAL SERVICES - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES GEOJIT FINANCIAL SERVICES INDOCO REMEDIES/
GEOJIT FINANCIAL SERVICES
 
P/E (TTM) x 135.5 16.7 810.8% View Chart
P/BV x 2.3 1.1 207.4% View Chart
Dividend Yield % 0.6 7.5 8.0%  

Financials

 INDOCO REMEDIES   GEOJIT FINANCIAL SERVICES
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
GEOJIT FINANCIAL SERVICES
Mar-18
INDOCO REMEDIES/
GEOJIT FINANCIAL SERVICES
5-Yr Chart
Click to enlarge
High Rs317147 215.9%   
Low Rs17858 307.1%   
Sales per share (Unadj.) Rs113.114.0 804.8%  
Earnings per share (Unadj.) Rs4.53.1 145.1%  
Cash flow per share (Unadj.) Rs11.83.7 321.3%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.42.0 20.7%  
Book value per share (Unadj.) Rs73.223.4 312.6%  
Shares outstanding (eoy) m92.15237.87 38.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.27.3 30.0%   
Avg P/E ratio x55.533.3 166.6%  
P/CF ratio (eoy) x21.027.9 75.2%  
Price / Book Value ratio x3.44.4 77.3%  
Dividend payout %22.465.0 34.5%   
Avg Mkt Cap Rs m22,83024,382 93.6%   
No. of employees `0005.52.8 192.3%   
Total wages/salary Rs m2,2091,112 198.7%   
Avg. sales/employee Rs Th1,910.11,178.4 162.1%   
Avg. wages/employee Rs Th405.0392.0 103.3%   
Avg. net profit/employee Rs Th75.5258.2 29.2%   
INCOME DATA
Net Sales Rs m10,4193,342 311.8%  
Other income Rs m47338 13.9%   
Total revenues Rs m10,4663,680 284.4%   
Gross profit Rs m1,349964 139.9%  
Depreciation Rs m677143 475.2%   
Interest Rs m2357 3,220.5%   
Profit before tax Rs m4841,152 42.0%   
Minority Interest Rs m0-45 0.0%   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m72376 19.3%   
Profit after tax Rs m412732 56.2%  
Gross profit margin %12.928.9 44.9%  
Effective tax rate %15.032.6 45.8%   
Net profit margin %4.021.9 18.0%  
BALANCE SHEET DATA
Current assets Rs m5,3736,371 84.3%   
Current liabilities Rs m4,1572,330 178.4%   
Net working cap to sales %11.7120.9 9.7%  
Current ratio x1.32.7 47.3%  
Inventory Days Days680-  
Debtors Days Days73149 48.7%  
Net fixed assets Rs m6,244596 1,048.4%   
Share capital Rs m184238 77.5%   
"Free" reserves Rs m6,5665,336 123.0%   
Net worth Rs m6,7505,574 121.1%   
Long term debt Rs m1,2330-   
Total assets Rs m12,3638,520 145.1%  
Interest coverage x3.1158.8 1.9%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.80.4 214.9%   
Return on assets %5.28.7 60.3%  
Return on equity %6.113.1 46.4%  
Return on capital %9.020.0 45.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,76220 19,293.8%   
Fx outflow Rs m1,1433 45,736.0%   
Net fx Rs m2,61917 15,405.3%   
CASH FLOW
From Operations Rs m1,227588 208.6%  
From Investments Rs m-1,360-87 1,565.1%  
From Financial Activity Rs m-388-370 104.9%  
Net Cashflow Rs m-521133 -391.7%  

Share Holding

Indian Promoters % 59.2 30.6 193.5%  
Foreign collaborators % 0.0 33.5 -  
Indian inst/Mut Fund % 12.5 0.4 3,125.0%  
FIIs % 6.0 2.4 250.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 33.2 67.5%  
Shareholders   12,805 36,145 35.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   STC INDIA  TVS SRICHAKRA  ADANI PORTS & SEZ  RELIGARE ENT.  CHOLAMANDALAM INVEST.  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

GEOJIT FINANCIAL SERVICES Announces Quarterly Results (4QFY19); Net Profit Down 61.6% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, GEOJIT FINANCIAL SERVICES has posted a net profit of Rs 74 m (down 61.6% YoY). Sales on the other hand came in at Rs 712 m (down 18.3% YoY). Read on for a complete analysis of GEOJIT FINANCIAL SERVICES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

INDOCO REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 76.4% (Quarterly Result Update)

Jan 24, 2019 | Updated on Jan 24, 2019

For the quarter ended December 2018, INDOCO REMEDIES has posted a net profit of Rs 53 m (down 76.4% YoY). Sales on the other hand came in at Rs 3 bn (down 5.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 13, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS